Biophysics in drug discovery: impact, challenges and opportunities

Renaud JP, Chung C-w, Danielson UH, Egner U, Hennig M, Hubbard RE & Nar H (2016) Nature Reviews Drug Discovery, 15:679–698, doi:10.1038/nrd.2016.123AbstractOver the past 25 years, biophysical technologies such as X‑ray crystallography, nuclear magnetic resonance spectroscopy, surface plasmon resonance spectroscopy... [...]

Identification and Characterization of an Irreversible Inhibitor of CDK2

Elizabeth Anscombe, Elisa Meschini, Regina Mora-Vidal, Mathew P. Martin, David Staunton, Matthis Geitmann, U. Helena Danielson, Will A. Stanley, Lan Z. Wang, Tristan Reuillon, Bernard T. Golding, Celine Cano, David R. Newell, Martin E.M. Noble, Stephen R. Wedge, Jane A. Endicott and Roger J. Griffin (2015) Chemistry & Biology 22:1–6.Summary Irreversible... [...]

Structural basis of ligand recognition in 5-HT3 receptors

Divya Kesters, Andrew J. Thompson, Marijke Brams, Rene´ van Elk, Radovan Spurny, Matthis Geitmann, Jose M. Villalgordo, Albert Guskov, U. Helena Danielson, Sarah C. R. Lummis, August B. Smit and Chris Ulens (2013), EMBO reports, Jan 3;14(1) Abstract The 5-HT3 receptor is a pentameric serotonin-gated ion channel,... [...]

Aliskiren displays long-lasting interactions with human renin

Gossas T, Vrang L, Henderson I, Sedig S, Sahlberg C, Lindström E, Danielson U. H. (2012) N-S Arch. Pharmaco. 385(2);219-24 Abstract Aliskiren is a selective renin inhibitor recently approved for use in hypertension. Efficacy duration appears longer than what would be expected based on its circulating half-life.... [...]